GCell Holds 'Science Day' with Experts in Cell and Gene Therapy

Sharing the Latest Research Trends in the CGT Field

GC Cell announced on the 20th that it formed a Scientific Advisory Board (SAB) composed of world-renowned experts in the field of cell and gene therapy (CGT) and held a 'Science Day' event at its headquarters in Yongin, Gyeonggi Province on the 19th.

GCell Holds 'Science Day' with Experts in Cell and Gene Therapy

GCell announced on the 20th that it held a "Science Day" at its headquarters in Yongin on the 19th. James Park, CEO of GCell (4th from the left), and Ho-won Kim, CTO (1st from the right), along with other participants, are taking a commemorative photo.
[Photo by GCell]

Science Day was newly planned this year as a platform for technological exchange, inviting global CGT experts to share the latest research trends and explore future development strategies.

GC Cell's Scientific Advisory Board (SAB) consists of six domestic and international experts in the CGT field, including Professor Jae-Hong Park of Memorial Sloan Kettering Cancer Center, an expert in chimeric antigen receptor (CAR)-T therapy research and clinical development; Professor Eric Smith of Harvard Dana-Farber Cancer Center; Professor Magnus Essand of Uppsala University's Department of Immunogenetics and Pathology; Professor Jong-Chul Park of Massachusetts General Hospital Head and Neck Cancer Center; Professor Won-Seok Kim of Samsung Medical Center's Oncology Department; and Professor Deok-Hyun Yoon of Asan Medical Center's Oncology Department.

The event featured five SAB members as speakers and was conducted over two sessions with five lectures in total. In the first session, topics included clinical experience cases of early CD19 CAR-T therapies and strategic approaches for next-generation therapies (Professor Jae-Hong Park), as well as clinical development experience with a new target antigen 'GPRC5D' attempted as an alternative to multiple myeloma treatment (BCMA CAR-T) and approaches to dual target CAR therapies (Professor Eric Smith).

In the second session, the latest insights on CGT across various cancer types were shared under themes such as CAR-T enhancement strategies in solid tumors (Professor Magnus Essand), clinical experience and potential opportunities of cell therapies for head and neck cancer (Professor Jong-Chul Park), and clinical experience with NK cell therapies for B-cell non-Hodgkin lymphoma patients (Professor Deok-Hyun Yoon).

James Park, CEO of GC Cell, stated, "It was a meaningful occasion where innovative discussions took place regarding diverse therapeutic experiences, directions, and possibilities in research and development with world-class experts. Moving forward, through continuous consultations, we will leverage the SAB members' abundant knowledge and clinical experience in research, development, clinical trials, and commercialization strategies to secure global competitiveness and leap forward as a global top-tier CGT company."